180 related articles for article (PubMed ID: 20374029)
1. Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.
Longo R; D'Andrea M; Sarmiento R; Gasparini G
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S41-50. PubMed ID: 20374029
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
Jabir RS; Naidu R; Annuar MA; Ho GF; Munisamy M; Stanslas J
Pharmacogenomics; 2012 Dec; 13(16):1979-88. PubMed ID: 23215890
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of breast cancer therapies.
Hertz DL; McLeod HL; Hoskins JM
Breast; 2009 Oct; 18 Suppl 3():S59-63. PubMed ID: 19914545
[TBL] [Abstract][Full Text] [Related]
5. Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer.
Tang SC
Cancer Invest; 2009 Feb; 27(2):206-14. PubMed ID: 19235594
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
9. Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety.
Yardley DA
Clin Breast Cancer; 2010 Apr; 10(2):119-29. PubMed ID: 20353933
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Niculescu-Duvaz I
Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
[TBL] [Abstract][Full Text] [Related]
11. Treatment of metastatic breast cancer: looking towards the future.
Amar S; Roy V; Perez EA
Breast Cancer Res Treat; 2009 Apr; 114(3):413-22. PubMed ID: 18465221
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics in breast cancer therapy.
Tan SH; Lee SC; Goh BC; Wong J
Clin Cancer Res; 2008 Dec; 14(24):8027-41. PubMed ID: 19088019
[TBL] [Abstract][Full Text] [Related]
13. [Individualized treatment of breast cancer].
Eucker J; Possinger K
Dtsch Med Wochenschr; 2011 Mar; 136(10):486-91. PubMed ID: 21365526
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab and capecitabine for metastatic breast cancer.
Med Lett Drugs Ther; 1998 Nov; 40(1039):106-8. PubMed ID: 9814369
[No Abstract] [Full Text] [Related]
15. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.
Baselga J; Carbonell X; Castañeda-Soto NJ; Clemens M; Green M; Harvey V; Morales S; Barton C; Ghahramani P
J Clin Oncol; 2005 Apr; 23(10):2162-71. PubMed ID: 15800309
[TBL] [Abstract][Full Text] [Related]
16. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
Colozza M; de Azambuja E; Personeni N; Lebrun F; Piccart MJ; Cardoso F
Oncologist; 2007 Mar; 12(3):253-70. PubMed ID: 17405890
[TBL] [Abstract][Full Text] [Related]
17. [Indications for Herceptin in breast cancer treatment].
Beuzeboc P
Gynecol Obstet Fertil; 2004 Feb; 32(2):164-72. PubMed ID: 15123142
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in the treatment of breast cancer.
Sirohi B; Smith K
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1559-68. PubMed ID: 18925848
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
Angelini S; Botticelli A; Onesti CE; Giusti R; Sini V; Durante V; Strigari L; Gentile G; Cerbelli B; Pellegrini P; Sgroi V; Occhipinti M; DI Pietro FR; Rossi A; Simmaco M; Mazzuca F; Marchetti P
Anticancer Res; 2017 May; 37(5):2633-2639. PubMed ID: 28476838
[TBL] [Abstract][Full Text] [Related]
20. [Clinical aspects of trastuzumab treatment in breast cancer].
Grell P; Svoboda M; Fabián P; Petráková K; Vyzula R
Klin Onkol; 2009; 22(1):3-10. PubMed ID: 19534433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
